The OPA of RISH was over 80% compared with the FDA-approved IHC method, and our study illustrated the possible application of RISH as a complementary diagnostic test, providing accurate detection of PD-L1 in NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.